MedTrace Logo

The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial

NCT00468533 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-05-02

No results posted yet for this study

Summary

A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.

Conditions

  • Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome

Interventions

DRUG

Aripiprazole

Sponsors & Collaborators

  • Yu-Li Hospital

    lead OTHER

Principal Investigators

  • Tsuo-Hung Lan, MD, PhD · Yu-Li Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00468533 on ClinicalTrials.gov